Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
AboutMethodSourcesNewsletter
StockCIK 1082554

UNITED THERAPEUTICS Corp (UTHR): Insider Trades and Fund Holdings

In the past 12 months, UNITED THERAPEUTICS Corp insiders reported 0 open-market purchases worth $0 and 60 sales worth $283.7M; 59 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months
$0Bought by insiders, 12 months
$283.7MSold by insiders, 12 months
2Tracked funds holding

Timeline: news and trades

Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.

  1. Oct 26, 2026Insider saleCEO Martine A. Rothblatt sold $5.6 million under a 10b5-1 plan
  2. Oct 23, 2026Insider saleCEO Martine A. Rothblatt sold $5.5 million under a 10b5-1 plan
  3. Oct 22, 2026Insider saleCEO Martine A. Rothblatt sold $5.5 million under a 10b5-1 plan
  4. Oct 21, 2026Insider saleCEO Martine A. Rothblatt sold $5.3 million under a 10b5-1 plan
  5. Oct 20, 2026Insider saleCEO Martine A. Rothblatt sold $5.3 million under a 10b5-1 plan
  6. Oct 19, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  7. Oct 16, 2026Insider saleCEO Martine A. Rothblatt sold $5.1 million under a 10b5-1 plan
  8. Oct 15, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  9. Oct 15, 2026Insider saleGeneral Counsel Paul A. Mahon sold $4.5 million under a 10b5-1 plan
  10. Oct 15, 2026Planned salePAUL MAHON (officer) filed notice to sell about $4.5 million around Oct 15, 2026
  11. Oct 14, 2026Insider saleCEO Martine A. Rothblatt sold $5.1 million under a 10b5-1 plan
  12. Oct 13, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  13. Oct 12, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  14. Oct 9, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  15. Oct 8, 2026Insider saleCEO Martine A. Rothblatt sold $5.1 million under a 10b5-1 plan
  16. Oct 7, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  17. Oct 6, 2026Insider saleCEO Martine A. Rothblatt sold $5.1 million under a 10b5-1 plan
  18. Oct 5, 2026Insider saleCEO Martine A. Rothblatt sold $5.1 million under a 10b5-1 plan
  19. Oct 2, 2026Insider saleCEO Martine A. Rothblatt sold $5.2 million under a 10b5-1 plan
  20. Oct 1, 2026Insider saleCEO Martine A. Rothblatt sold $5.5 million under a 10b5-1 plan
  21. Oct 1, 2026Insider saleGeneral Counsel Paul A. Mahon sold $4.7 million under a 10b5-1 plan
  22. Oct 1, 2026Planned saleMARTINE ROTHBLATT (director, officer) filed notice to sell about $113.3 million around Oct 1, 2026
  23. Oct 1, 2026Planned salePAUL MAHON (officer) filed notice to sell about $4.7 million around Oct 1, 2026
  24. Sep 30, 2026Insider saleCEO Martine A. Rothblatt sold $5 million under a 10b5-1 plan
  25. Sep 29, 2026Insider saleCEO Martine A. Rothblatt sold $4.5 million under a 10b5-1 plan
  26. Sep 28, 2026Insider saleCEO Martine A. Rothblatt sold $4.6 million under a 10b5-1 plan
  27. Sep 25, 2026Insider saleCEO Martine A. Rothblatt sold $4.5 million under a 10b5-1 plan
  28. Sep 24, 2026Insider saleCEO Martine A. Rothblatt sold $4.5 million under a 10b5-1 plan
  29. Sep 23, 2026Insider saleCEO Martine A. Rothblatt sold $4.7 million under a 10b5-1 plan
  30. Sep 22, 2026Insider saleCEO Martine A. Rothblatt sold $4.7 million under a 10b5-1 plan
  31. Sep 21, 2026Insider saleCEO Martine A. Rothblatt sold $4.7 million under a 10b5-1 plan
  32. Sep 18, 2026Insider saleCEO Martine A. Rothblatt sold $4.7 million under a 10b5-1 plan (10 days after: signed a material agreement)
  33. Sep 17, 2026Insider saleCEO Martine A. Rothblatt sold $4.7 million under a 10b5-1 plan (9 days after: signed a material agreement)
  34. Sep 17, 2026Insider saleGeneral Counsel Paul A. Mahon sold $4.1 million under a 10b5-1 plan (9 days after: signed a material agreement)
  35. Sep 17, 2026Planned salePAUL MAHON (officer) filed notice to sell about $4.1 million around Sep 17, 2026
  36. Sep 16, 2026Insider saleCEO Martine A. Rothblatt sold $4.8 million under a 10b5-1 plan (8 days after: signed a material agreement)
  37. Sep 15, 2026Insider saleCEO Martine A. Rothblatt sold $4.8 million under a 10b5-1 plan (7 days after: signed a material agreement)
  38. Sep 14, 2026Insider saleCEO Martine A. Rothblatt sold $4.8 million under a 10b5-1 plan (6 days after: signed a material agreement)
  39. Sep 14, 2026Insider saleDirector Nilda Mesa sold $115,338 (6 days after: signed a material agreement)
  40. Sep 14, 2026Planned saleNILDA MESA (director) filed notice to sell about $115,338 around Sep 14, 2026

Showing the latest 40 of 70 events.

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 27, 2026.

Recent UTHR insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHoldingFiling
Oct 27Oct 26Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500588.64$5.59M−2.8%Form 4 ↗
Oct 26Oct 23Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500582.76$5.54M−2.8%Form 4 ↗
Oct 23Oct 22Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500583.38$5.54M−2.8%Form 4 ↗
Oct 22Oct 21Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500560.07$5.32M−2.8%Form 4 ↗
Oct 21Oct 20Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500553.87$5.26M−2.8%Form 4 ↗
Oct 20Oct 19Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500543.32$5.16M−2.8%Form 4 ↗
Oct 19Oct 16Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500534.66$5.08M−2.8%Form 4 ↗
Oct 16Oct 15Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500546.65$5.19M−2.8%Form 4 ↗
Oct 16Oct 15Paul A. MahonGeneral CounselGeneral Counsel▼ SELL10b5-18,300544.30$4.52M−16%Form 4 ↗
Oct 15Oct 14Martine A. RothblattCEOCEO (ind.)▼ SELL10b5-19,500539.99$5.13M−2.8%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
All 60 UTHR insider trades →

Insiders who traded in the past year

InsiderRoleBuysBoughtSellsSoldLatest
Martine A. RothblattCEO0$054$261.9MOct 27, 2026
Paul A. MahonGeneral Counsel0$05$21.7MOct 16, 2026
Nilda MesaDirector0$01$115KSep 15, 2026

Buybacks and executive pay

UNITED THERAPEUTICS Corp spent $1 billion buying back its own shares in 2025.

YearCEO pay reportedCEO pay "actually paid"Value of $100 invested
2025$18.0M$149.9Mn/a
2024$23.0M$120.3Mn/a
2023$17.0M−$10.8Mn/a

From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.

Tracked funds that report UTHR

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

FundQuarterSharesValue% of portfolioChange
Renaissance TechnologiesQ2 20261,708,739$925.8M1.27%▼ −4.4%
Bridgewater AssociatesQ2 2026111,326$60.3M0.25%▲ +0.1%
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →